A Better Newspaper

## Overview A June 2026 preprint identifies melanin-concentrating hormone (MCH) neurons in the lateral hypothalamus as a critical node disrupted by tau pathology in a mouse model of Alzheimer's disease (AD), providing a potential circuit mechanism linking tauopathy to sleep-wake dysfunction (bioRxiv:2026.05.31.729026). ## Key Findings Using longitudinal EEG/EMG recordings in PS19 mice (a tauopathy model), the researchers report: - Progressive impairments in sleep architecture and homeostasis over time - Significant degeneration of MCH neurons in the lateral hypothalamus at late stages of tauopathy - Co-degeneration of neighboring hypocretin (Hcrt/orexin) neurons in the same region (bioRxiv:2026.05.31.729026) ## Mechanistic Significance Sleep disruption is described as an early and pervasive feature of Alzheimer's disease, but the circuit mechanisms linking tau pathology to sleep-wake dysfunction had remained unresolved. This work proposes MCH neurons as a specific, anatomically localized mediator of this relationship. The co-degeneration of hypocretin neurons is particularly notable: hypocretin loss is the established mechanism of narcolepsy, suggesting that AD-related sleep disruption may share mechanistic features with narcolepsy. ## Therapeutic and Diagnostic Implications - MCH receptor antagonists or MCH pathway modulators could become therapeutic targets for AD-related sleep disruption - Lateral hypothalamus neuronal integrity may become a biomarker for tauopathy progression - The findings could support clinical trials testing sleep-targeting interventions in early AD ## Connections to Broader Neurodegeneration Research This work connects to growing interest in sleep as both a biomarker and potential modifier of AD progression, including research on meningeal lymphatic drainage and amyloid clearance during sleep. ## Outlook The MCH neuron finding is likely to stimulate follow-on research in human post-mortem tissue and potentially inform clinical trial design for AD sleep interventions.